RIP Woody Williams, the last surviving MOH recipient from WW2. All gone. All 472. WWII Memorial Friends

Great article on a frequent topic of conversation with patients. There is science between the association of diet and the prevention and treatment of cancer. ⁦Cancer Discovery⁩ ⁦SWOG Cancer Research Network⁩ ⁦UC College of Medicine⁩ aacrjournals.org/cancerdiscover…

ESPAC 5 Trial Results Published.

Yale Cancer Center is filled with pride that Pat LoRusso is a nominee for AACR president, with ballot opening today. We are all 100% behind her, and I know she will be an extraordinary leader for AACR. Yale Cancer Center Smilow Cancer Hospital

1/2: ASCO GI Abstracts are out. Some highlights to follow: 1. Abstract 1. ctDNA for response assessment. 2. Abstract 5. Kinetics of cfDNA on MRD 3. Abstract 6. Final results of OPERA 4. Abstract 488. SBRT for HCC. 5. LBA490. Results of SWOG 1815.

AACR Members: Voting is currently open through February 28 for the following AACR offices: —President-Elect —Board of Directors (5 seats) —Nominating Committee (4 seats) Read the candidates' vision statements and cast your votes today: bit.ly/3ZMIZwa

Don’t forget to vote for AACR⁩ leadership! I have been lucky to work with #PatLoRusso on Phase 1 trials/UM1 and #JohnCarethers who is our VCHS ⁦UC San Diego School of Medicine⁩ and an amazing physician-scientist in equitable CRC prevention - great candidates! directvote.net/aacr/login.asp…

Pat LoRusso is brilliant, inspiring, caring, always focused on the next best step for patients and for cancer research. As a young oncologist who has experienced first-hand her leadership and mentorship, I know she would be an outstanding leader for AACR. Yale Cancer Center

Please vote for Dr. Patricia LoRusso as the next AACR president! A true champion for patients, advocate of bench-bedside research and longtime AACR contributor!

The Smilow Hospitalist Service is currently seeking internal medicine, palliative care trained, and hematology-oncology trained physicians to join our team. Let’s accomplish great things together! Email [email protected] with inquiries. Smilow Cancer Hospital Yale New Haven Health PallMedEd

#GI24 Dr. Fernandez: Analysis of WW databases suggests patients with Local Regrowth have high risk (22%) of Distant Metastases. IMO, WW should be done on clinical trial when possible ➡️ JANUS.⁦ ⁦Josh Smith, MD, PhD, FACS⁩ ⁦Mark Whiteford⁩ ⁦⁦Arvind Dasari, MD, MS⁩

According to a JAMA study, around 1/3 of academic physicians across specialties expressed "intent to leave" their current institution. Factors like burnout & lack of professional fulfillment were significant contributors. Where does your specialty fall on this chart?

In DC to plan #ASCO 24: as riding bike saw blue flags on the mall to raise colon cancer awareness, especially in young adults. Haiku to honor colon cancer awareness + our patients. Spring's cherry blossoms Colon cancer’s silent threat Awareness ASCO spreads ASCO Kimmie Ng, MD, MPH

Not all radioresistant lung metastases treated with SBRT are created equal! 11% local failures for melanoma + sarcoma + renal cell and 33% for colorectal + endometrial (2% for others). BED10>=100 matters, especially for colorectal. Yale Radiation Oncology Residency Yale Cancer Center advancesradonc.org/article/S2452-…

I will be riding in my 6th closer to free bike ride on 9/7/2024. The ride is a great experience to join the Yale Cancer Center community and support cancer research. Please support my ride at the following link: rideclosertofree.org/participant/31… My goal is to raise at least $500!

I will be speaking at the 4th Binaytara Precision Oncology Summit this October 5th and 6th in San Francisco. My talk will be on the next generation of DNA repair targeted treatments! You can register here: education.binayfoundation.org/content/4th-bi…

We have compared the performance ctDNA by Natera vs. imaging in curatively resected colorectal cancer on surveillance. Signatera missed 31% of recurrences (+ imaging and negative Signatera). Largest study of comparative strategies. jamanetwork.com/journals/jaman…

Ph1 data from a new CEACAM5 topo1 ADC (Precemtabart tocentecan 😵‍💫) in mCRC (n=40). Modest activity (ORR 7.5%), maybe due to cross-resistance with prior irinotecan. Several DLTs, including G5 sepsis in an obese pt. Important to cap ADC doses in these pts! nature.com/articles/s4159…

I will be competing in my 7th Closer to Free bike ride on Sept 6 2025 to help raise funds for Yale Cancer Center and GI Research! Please support by ride by donating at the following link: rideclosertofree.org/participants/3…

🎉 Proud to announce publication by ⁦Janie Y. Zhang, MD⁩ “High MGMT expression identifies aggressive #CRC w distinct genomic features & immune evasion properties.” Great step forward n understanding CRC biology!🔬 UPMC Hillman Cancer Center ⁦UPMC Physician Resources⁩ jitc.bmj.com/content/13/9/e…